Key facts
- Identity question
- Is this the intended molecule?
- Purity question
- How much of what was detected is that molecule?
- Typical identity methods
- Mass spectrometry, MS/MS sequencing, reference-standard comparison
- Typical purity method
- Reversed-phase HPLC with UV detection
- Separate third question
- Quantity: how much peptide is in the container?
- Method that links the two
- LC-MS, which pairs retention time with mass
What is the difference between identity and purity?
Identity tells you what the molecule is. Purity tells you how much of the sample is that molecule rather than something else.
People blur the two because one document often reports both, and a high purity figure feels like it ought to imply the right compound. It doesn't. An HPLC run can show a single sharp peak holding 99% of the signal and still say nothing about whether that peak is the intended sequence. A mass spectrum, for its part, can show the expected mass without telling you what fraction of the sample it represents. That is why quality frameworks for synthetic peptides treat identity and purity as separate attributes, each with its own test and acceptance criterion [1].
How is identity tested?
To test identity, you measure properties specific to the intended molecule. Usually that means its mass and, for stronger evidence, its sequence.
| Evidence | What it shows | Limitation |
|---|---|---|
| Retention time alone | The sample elutes where the expected compound elutes under one method | Many molecules can share a retention time |
| Intact mass by MS | The observed mass matches the theoretical mass of the sequence | Isomers and some sequence variants share the same mass |
| Retention time plus mass (LC-MS) | The expected mass appears at the expected time | Still cannot separate every isomer |
| MS/MS fragment sequence | Fragment ladders match the expected residue order | Standard methods do not tell leucine from isoleucine |
| Comparison with a reference standard | The sample matches an authenticated standard under the same conditions | Requires access to a qualified standard |
Mass spectrometry does most of the work with peptides because it measures a property tied directly to composition. Tandem mass spectrometry goes a step further and reads residue order from fragment ions [2]. Pharmacopeial work on peptide quality anchors identity assignments to well-characterized reference standards [3]. The instruments themselves are covered in how mass spectrometry works.
How is purity tested?
Purity testing splits the sample into its components and asks what share of the total signal belongs to the intended compound. Reversed-phase HPLC is the usual tool.
What comes out is a relative figure, typically area percent at a UV wavelength where peptide bonds absorb. It can only reflect what the method separates and detects. An impurity that co-elutes with the main peak, or barely absorbs at the chosen wavelength, gets under-counted or missed [4]. What HPLC purity means walks through the calculation and why the number can shift from one method to another.
Why can a sample be pure but not the right compound?
Purity only measures how uniform a sample is. It says nothing about what the sample is made of, so a pure sample can still be the wrong one.
Picture a synthesis where two neighboring amino acids were coupled in the wrong order. Purification could bring the product down to one sharp HPLC peak with a high purity figure, and it would still be a different peptide. The intact mass wouldn't change either, since the same residues are present. Only sequence-level evidence or a reference standard comparison would catch it. Sequence isomers, epimers formed by racemization during synthesis, and leucine/isoleucine substitutions all share the mass of the intended peptide [1][4].
A matching intact mass rules out many errors, but not all of them. Swapped residues, D-amino acid epimers and leucine/isoleucine substitutions leave the mass unchanged. When those risks matter, look for orthogonal evidence such as MS/MS data or a reference standard comparison.
Why can a sample be the right compound but impure?
This happens when the intended molecule is present, and confirmed by mass, but sits alongside significant amounts of related substances.
Solid-phase peptide synthesis adds one residue at a time. Any coupling or deprotection step that falls short leaves behind deletion sequences, truncated chains or residues still carrying protecting groups [4]. Mass spectrometry will happily confirm the expected mass in that sample, because the target is there. What it won't show is how much of the material is target and how much is related impurity; that takes a separation-based purity test. Some of these impurities are structurally very close to the parent. In one LC-high-resolution MS study of synthetic oxytocin, researchers identified and quantified several of them next to the main component [5]. For where these by-products come from, see peptide synthesis.
Identity vs. purity: the four possible outcomes
Set identity and purity side by side and you get four possible outcomes. Only one describes a well-characterized sample.
| Identity confirmed? | Purity high? | What it means |
|---|---|---|
| Yes | Yes | The intended molecule with few detected impurities: a well-characterized result |
| Yes | No | The intended molecule is present alongside significant related impurities |
| No | Yes | A uniform sample of something other than the intended molecule |
| No | No | A mixture whose main component is not the intended molecule |
Quantity is a third question altogether. Neither an identity test nor an HPLC purity figure tells you how much peptide is in a container. Lyophilized peptides hold water and counter-ions such as trifluoroacetate or acetate, so the peptide's share of the weighed powder, called net peptide content, has to be measured separately [6]. The peptide purity page goes further into purity versus quantity.
How LC-MS connects identity and purity
LC-MS measures the mass of whatever elutes at each point in the chromatogram, which lets you assign each peak to a molecule. That is the bridge between identity and purity.
In an LC-MS run you can show that the main peak carries the expected mass and give smaller peaks tentative identities from their masses. Useful as that link is, it doesn't merge the two questions. Purity is still normally reported from UV data, because a mass spectrometer's response depends on how efficiently each species ionizes [2][5]. The combined technique is described in what LC-MS is, and HPLC vs. mass spectrometry compares the methods one by one.
What to look for on a COA
A complete certificate of analysis lists identity and purity as separate results. Each names its own method, and both carry the same batch reference.
- An identity result naming the technique, for example ESI-MS, with observed and theoretical masses.
- A purity result naming the technique, for example RP-HPLC at 214 nm, with the chromatogram attached.
- The same batch or lot number on both results.
- Nothing implying that one result can stand in for the other.
For the full list of fields, read what a COA should contain. The peptide testing hub gives an overview of methods, and the peptide glossary defines the terms used here.
FAQFrequently asked questions
Does high purity prove a peptide is the right compound?
No. Purity measures how much of the detected signal belongs to one main component, and it says nothing about what that component is. A peptide with a wrong or swapped residue can be purified down to a single clean HPLC peak. Identity has to be shown separately, usually by mass spectrometry, tandem MS sequencing or an authenticated reference standard.
Does a correct mass prove a peptide is pure?
No. Seeing the expected mass confirms the intended molecule is present. It doesn't tell you how much of the sample it makes up, which is why identity and purity are checked separately. Deletion or truncated sequences can be there in significant amounts, and peak heights in a mass spectrum don't reliably reflect quantity. For purity you need a separation-based method, typically HPLC with UV detection.
Which test confirms peptide identity?
Mass spectrometry is the usual identity test for peptides, since molecular mass is tied directly to composition. For stronger confirmation, tandem mass spectrometry reads the sequence from fragment ions, or the sample is matched against a qualified reference standard under the same conditions. Retention time by itself is weak identity evidence.
Can two different peptides have the same mass?
Yes. Rearrange the same amino acids into a different order and the mass stays identical. The same goes for a leucine/isoleucine swap or a change in the configuration of one amino acid. Intact mass can't separate these cases. You need chromatographic separation, fragmentation data or a reference standard comparison.
Where does quantity fit in?
Quantity is its own question, separate from identity and purity: how much peptide is actually in the container? Lyophilized peptides carry water and counter-ions, so the weighed powder isn't all peptide. Net peptide content is measured with methods such as amino acid analysis, and it can come in noticeably lower than the HPLC purity figure.
Why do COAs report both HPLC and mass spectrometry?
Because identity and purity are different questions. HPLC shows how much of the detected material is the main component, which gives you a purity figure. Mass spectrometry shows whether that component has the expected mass, which is identity evidence. Together they describe the sample far better than either one alone, as long as both cite the same batch and state their methods.
REFScientific references
-
Vergote V, Burvenich C, Van de Wiele C, et al. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci. 2009;15(11):697-710. PubMed 19750489
review (pharmacopeial specifications) -
Steen H, Mann M. The ABC's (and XYZ's) of peptide sequencing. Nat Rev Mol Cell Biol. 2004;5(9):699-711. PubMed 15340378
review -
McCarthy D, Han Y, Carrick K, et al. Reference Standards to Support Quality of Synthetic Peptide Therapeutics. Pharm Res. 2023;40(6):1317-1328. PubMed 36949371
review (pharmacopeial reference standards) -
D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. PubMed 25044089
review -
Li M, Josephs RD, Daireaux A, et al. Structurally related peptide impurity identification and accurate quantification for synthetic oxytocin by liquid chromatography-high-resolution mass spectrometry. Anal Bioanal Chem. 2021;413(7):1861-1870. PubMed 33479819
analytical method study -
Hoofnagle AN, Whiteaker JR, Carr SA, et al. Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays. Clin Chem. 2016;62(1):48-69. PubMed 26719571
consensus recommendations
Research Library
Research Library
Testing & Analysis